Clinical Trial Update: To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating QL1206 and Xgeva for bone metastases from solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases

Drugs mentioned

• QL1206 (denosumab)
• Xgeva (denosumab)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Bone Metastases | Phase 3 | Status: UNKNOWN